SW North America, a leading supplier of horizontal multi- and single-spindle CNC machining centers, automation, and complete system solutions, announced its annual Open House will return to its North American headquarters at 30160 Lyon Industrial Court, New Hudson, Michigan 48165 on Friday, August 8, 2025.
This Open House will center around a duel themes, a medical deep dive and an aerospace focus. Attendees will gain a firsthand look at the machining technologies and system solutions that support some of the most demanding industries, including medical technology, automotive and electric vehicles, aerospace, and agriculture and construction, among others.
Highlights include the following:
Live machining demonstrations featuring the BA 322i, a twin-spindle CNC machining center showcasing the creation of a tibia spacer, a critical component used in total knee prosthetics, as well as the BA space3, machining a wing rig rib for aircraft, demonstrating capabilities in size, speed, and stability.
Facility tours of SW’s 33,000 square foot North American headquarters.
Lunch, live entertainment, and a raffle/drawing.
Networking with SW engineers, executives, and vendor partners.
Technology insights into SW’s multi-spindle machining, automation, and self-sufficient production cells.
Special guests and speakers to be announced.
“We look forward to welcoming our customers, partners, and the local community into our facility,” said Andrew Rowley, General Sales Manager, SW North America, Inc. “This year’s focus on aerospace and medical machining highlights our expertise in precision manufacturing while offering a fun and engaging experience for everyone who attends.”
SW’s portfolio includes compliance and experience with ITAR, FFL, and ISO standards, giving customers the confidence to partner on regulated, high-precision work.
Registration is free and open to anyone interested in smart manufacturing, automation, or advanced machining. Request a pass to attend by emailing contact.na@sw-machines.com or visiting: https://sw-machines.com/us/company/sw-machines-north-america-open-house/
About SW North America
SW North America is a subsidiary of Schwäbische Werkzeugmaschinen GmbH, a leading international manufacturer of smart manufacturing solutions. With its North American headquarters in Michigan, SW is the world market leader in multi-spindle CNC machining centers for cutting a variety of materials across the automotive, electromobility, agricultural and construction machinery, medical technology, and aerospace industries.
SW currently has more than 1,700 employees across its global headquarters in Schramberg-Waldmössingen, Germany, and locations in China, France, Hungary, Mexico, Poland, and the United States. The company achieved a group turnover of $535 million in 2022. Learn more about SW North America athttps://sw-machines.com/us/.
MMS, a global, data-focused clinical research organization (CRO), has been named the winner of the 2025 Fierce CRO Award in the category of Excellence in Client Service and Partnership and the company’s CEO Dr. Uma Sharma has earned the CRO Champion Award, which recognizes leaders whose vision and values have shaped the future of clinical development.
Judged on innovation and impact, measurable outcomes, and scalability, MMS was selected as the top organization demonstrating a powerful commitment to building collaborative, long-term sponsor relationships.
“We are thrilled to be named the top CRO in two categories, and this is directly correlated to the trust that our clients place in us,” said Dr. Sharma. “At MMS, scientific integrity and client trust are inseparable. Together, they form the backbone of the long-standing partnerships we’re proud to cultivate across the globe. From large pharmaceutical sponsors to emerging biotech, we are honored to support them through the constantly evolving challenges of development and regulatory approvals. This award belongs to every global #OneMMS team member who brings our values to life.”
What Sets MMS Apart in Client Service
MMS serves as an extension of its clients by leveraging its science and data-focused colleagues, processes, and platforms, including AI, in a way that fosters adaptability and enhances continuous innovation, speed and quality. Highlights of its approach include:
Deep scientific and regulatory expertise that integrates seamlessly with Sponsor teams
Exceptionally low annual global team turnover, allowing for long-term continuity and knowledge retention on every program
Full end-to-end biometrics services embedding quality by design principles to de-risk drug development from trial design via KerusCloud® to submission
Proactive communication and planning when working with FDA, EMA, and other global health authorities, navigating accelerated pathways, and supporting emerging and first-in-class areas
Custom data analytics via Datacise®, providing actionable real-time visibility into study progress, supporting sponsor oversight and enabling ICH E6 (R3) compliance
A culture driven by SOUL (Sense of Urgency and Leadership), reflected in every interaction
“Winning the Excellence in Client Service award and having Uma named CRO Champion validates the micro-decisions and care we put into every sponsor relationship,” said Ben Dudley, Chief Commercial Officer at MMS. “In today’s increasingly complex R&D environment, our team’s focus on responsiveness, scientific depth, and proactive planning is truly making a difference, and we’re thankful that the industry is recognizing our approach firsthand today.”
MMS continues to expand its offerings, recently integrating KerusCloud®, a cloud-based statistical modeling platform, and enhancing its end-to-end REMS services through proprietary technology and regulatory leadership. These advancements, coupled with the company’s commitment to excellence, demonstrate how MMS continues to lead in service, science, and strategic partnerships.
MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, a 19-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating. For more information, visitwww.mmsholdings.com.
TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today a significant upgrade to its REGISTRY platform. For the first time, REGISTRY now includes artificial intelligence (AI) capabilities that automate and accelerate clinical trial registration and results disclosure by extracting structured data directly from unstructured protocol documents. This enhancement marks the first instance of embedded AI within the REGISTRY platform.
REGISTRY’s new AI functionality intelligently populates key clinical trial registration fields required by systems such as ClinicalTrials.gov. These fields range from basic free-text entries like clinical study descriptions to more complex, structured elements such as study design, participant groups, outcome measures, and associated interventions.
Powered by unique prompts designed to extract relevant data, the system does not generate new content or retain user data for model training to maintain strict security and compliance protocols. AI populates the required registration fields and maintains full field validation that adhere to registry requirements. It also allows teams to review and revise information before submission. This mirrors existing quality control and approval workflows, ensuring that each record meets organizational and regulatory standards.
Measurable improvements in cost, quality, and delivery can be expected, with key benefits that include the following:
Time savings: AI reduces manual effort in entering clinical trial data, helping Sponsors meet health authority registration timelines.
Improved accuracy: AI auto populates key clinical trial registration fields based on protocol source material, reducing input errors and inconsistencies.
Regulatory readiness: Built-in validation checks help reduce common system warnings or submission issues.
Security and control: All AI tasks are transactional and user-reviewed before submission, maintaining data governance.
“We designed this AI upgrade within REGISTRY to help Sponsors, CROs, and academic researchers reduce risk, improve accuracy, and accelerate clinical trial disclosure and transparency worldwide,” said Zach Weingarden, MS, Director of AI Technology & Applications at TrialAssure. “It was built to support both large-scale operations and lean academic teams, giving every user a better tool to register clinical studies more effectively.”
By reducing the need for manual data entry and offering smart validation aligned with global compliance rules through AI, REGISTRY significantly cuts the time it takes to prepare and register clinical trials. This helps users meet tight regulatory timelines and improves opportunities for earlier participant recruitment in clinical trials.
Integrated Support for CTIS and Document Anonymization
One area of growing complexity is the European Clinical Trials Information System (CTIS), which combines trial registration, regulatory submission, and public release of documentation into a single framework. TrialAssure REGISTRY’s AI upgrade supports this shift by streamlining data capture and enabling faster, more compliant submissions.
As regulatory expectations evolve, TrialAssure’s broader platform helps Sponsors prepare for full compliance. REGISTRY integrates seamlessly with TrialAssure ANONYMIZE®, which can support CTIS-related submissions by redacting or anonymizing required documents, data, and images before public release.
Weingarden added, “As one of our flagship tools, ANONYMIZE has already proven itself as a trusted solution for data, document, and image anonymization. Bringing it into the REGISTRY workflow adds another layer of efficiency that helps Sponsors meet CTIS and global disclosure standards with greater confidence and significantly less manual effort.”
TrialAssure continues to evolve its life science technology to anticipate industry needs. This AI-powered enhancement of REGISTRY connects to TrialAssure’s broader Design for Transparency™ framework, which prioritizes upfront clarity, regulatory alignment, and responsible data sharing.
Visit TrialAssure in booth #3049 at the BIO International Convention 2025 this week at the Boston Convention & Exhibition Center to speak more, or request a demo at https://www.trialassure.com/software/registry/.
ABOUT TRIALASSURE
TrialAssure® is an award-winning global data transparency company providing fast, intelligent, and cost-effective software and services for the pharmaceutical industry and related sectors. A recognized leader in artificial intelligence (AI) and machine learning (ML), TrialAssure offers AI Enabled, Human Driven™ solutions that support compliance through document and data anonymization, AI-assisted content development, compliance tracking, and clinical trial disclosure. Founded in 2009, TrialAssure’s global team builds proven technology platforms that help Sponsors and research organizations stay aligned with transparency regulations worldwide. TrialAssure was named Data Solution of the Year by the Data Breakthrough Awards. For more information, visit www.trialassure.com.
Company appoints Michael Arbitman as Executive Chief of Staff to accelerate platform execution
BOSTON (June 16, 2025) — Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announced the next phase of its flagship platform, Athena, at the BIO International Convention 2025. Building on the powerful workbench for clinical trial localization, Athena expands its services to create a total marketplace model designed to connect eCOA providers, translation freelancers, and clinical trial sponsors, among numerous others, in a unified ecosystem.
This evolution transforms Athena from a standalone solution into a connected platform where compliance, efficiency, global collaboration, and scalable execution converge. By aligning AI workflows with regulatory standards and integrating end-to-end tracking, Athena delivers a seamless, transparent experience that accelerates multilingual clinical trial operations.
“This update is a step forward for how regulated translation can operate in the clinical research industry overall,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “Athena now brings translators, reviewers, and life sciences teams into one connected system. It’s a smarter model that supports better outcomes across global studies.”
Athena’s new marketplace allows organizations to:
Engage qualified translation experts within the platform
Track version history and QA across language pairs
Maintain ISPOR-compliant workflows with built-in checkpoints
Eliminate vendor threads and siloed document tracking
Accelerate time-to-launch for global studies with flexible engagement options
The platform is built to support the real-world needs of eCOA vendors managing multilingual content, sponsors navigating global submissions, and qualified translators seeking structured, high-value work in regulated settings.
Leadership growth continues at Cliniphai
To support this next chapter, Cliniphai has appointed Michael Arbitman as Executive Chief of Staff. Formerly a top-level executive with Medidata, CARET Legal, and Fresh Direct, Arbitman brings decades of experience in product strategy, FDA-regulated systems, and Agile program delivery, and will lead execution across Athena’s growing marketplace environment
“I see a clear opportunity to help shape the future of Athena by building a strong operating model that supports global scale and regulatory clarity,” said Arbitman. “It’s a privilege to lead this work alongside a team that brings deep scientific and clinical expertise to every part of the platform.”
Arbitman is already leading implementation efforts on Athena for major global translation projects, including managing ISPOR-compliant Morisky Medication Adherence Scale (MMAS) workflows across five language pairs, country-specific PI reviewer coordination, and real-time QA reporting.
Cliniphai’s team will be at booth 1269 during BIO 2025 in Boston, connecting with partners across the translation, eCOA, and clinical technology space. To explore Athena’s marketplace model or speak with the team, visitwww.cliniphai.com.
About Cliniphai
Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences. Its flagship solution, Athena, is a marketplace-driven platform for clinical translation and localization that combines AI-powered workflows with built-in compliance and operational transparency. Designed to support sponsors, eCOA providers, and language experts alike, Athena enables secure, scalable, and collaborative execution across global studies. For more, visitwww.cliniphai.com.
Three Michigan-based companies—TSRL Inc., AnchorBio, and AAPharmaSyn—have announced the formation of The A2 BioPharm Collaborative, a new strategic collaboration aimed at accelerating drug development from target identification to IND-enabling studies. The announcement coincides with the companies’ joint presence at BIO 2025, one of the largest global biotechnology conferences, where they are co-located within the Michigan Pavilion inside the Boston Convention and Exhibition Center this week.
With complementary expertise across discovery biology, synthetic chemistry, and oral drug delivery, The A2 BioPharm Collaborative was created to deliver a seamless, cross-functional solution for biotech and pharmaceutical innovators seeking to move faster and smarter from first compound to first-in-human dose.
Understand how each organization works together, below:
AnchorBio brings biology-focused preclinical discovery services including target ID, assay development, and mechanism-of-action studies.
AAPharmaSyn offers deep capabilities in synthetic chemistry, process development, and lead optimization.
TSRL Inc. provides advanced formulation, PK/ADME, and preclinical development services with a focus on superior drug delivery.
“We have seen firsthand how difficult it is for teams to align chemistry, biology, and formulation early on. The A2 BioPharm Collaborative brings those disciplines together, creating a smarter way forward for biotech and pharma innovators,” said Dr. Elke Lipka, CEO of TSRL Inc. “Rooted in Michigan’s strong scientific community, our combined expertise helps early-stage developers all over the world reduce complexity and build real momentum toward the clinic.”
The collaborative’s launch comes at a time when biotech companies face increasing pressure to validate drug candidates quickly while conserving capital. The integrated services offered by The A2 BioPharm Collaborative are designed to streamline decision-making, reduce fragmentation, and improve outcomes across the R&D pipeline.
Attendees of BIO 2025 can meet with representatives from all three companies at their shared kiosk within the Michigan Pavilion. For more information, visit www.tsrlinc.com, www.anchorbiosolutions.com, and www.aapharmasyn.com.
After two years of development, Don F. McLean, founder of McLean Media and global speaker on personal branding, has officially launched his first book, The In Crowd for LinkedIn Mastery: Powering Your Path to Professional Success & Thought Leadership Through a PR Mindset.
Blending years of communications expertise with a fresh, Public Relations (PR) driven perspective, the book teaches professionals across nearly all industries how to elevate their presence on LinkedIn with intention, confidence, and strategic storytelling. Now available on Amazon, this text is rooted in the power of personal PR to help people show up online in ways that open doors and attract the right opportunities.
“This book is personal,” said McLean. “After nearly two decades in public relations, I wanted to give people a practical, empowering way to take control of their voice on LinkedIn. I’ve spent the last two years writing, refining, and speaking about these ideas, and now, I finally get to share them with the world.”
Key themes in The In Crowd for LinkedIn Mastery include:
How to craft a magnetic LinkedIn profile that reflects your unique value
The mindset shift from resume to reputation
Posting strategies that build trust, not just traffic
How to grow your influence with or without a big following
Content ideas that speak to your audience and position you as a thought leader
The power of public praise, comments, and strategic engagement
Leading up to the book’s release, McLean has been invited to speak at numerous conferences across the U.S. and internationally, including a recent keynote in Dublin, Ireland. His approach is helping communicators, students, and business professionals reimagine LinkedIn as a platform for real connection to focus their mindset on the entire expanse of their career and be engaged to meet and exceed their goals.
The In Crowd for LinkedIn Mastery is now available in paperback and Kindle editions on Amazon. It’s ideal for all levels of professionals from interns to CEOs, as well as job seekers, entrepreneurs, and anyone else ready to rethink what it means to be seen.Buy your copy today at https://www.amazon.com/dp/B0FCMCLPDD.
Findings reveal significant AI adoption in insurance, but governance, change management, and lack of AI fluency limit growth and improved customer experiences
Genpact (NYSE: G), an advanced technology services and solutions company, in collaboration with Amazon Web Services (AWS), today released a new report, Harness the winds of change: How to scale AI and build trust in insurance.With 69% of insurance companies having deployed AI but only 36% of US customers seeing an improved digital experience, the report underscores how the insurance industry still needs to scale AI to meet evolving customer expectations and accelerate growth. It also provides a strategic blueprint for overcoming adoption barriers to unlock AI’s transformative potential.
“We conducted this study to shed light on the untapped potential of AI in the insurance sector,” said Adil Ilyas, Global Business Leader, Insurance, Genpact. “While many insurers have made strides in adopting AI, significant opportunities remain to scale its impact. By aligning AI strategies with customer expectations and operational goals, insurers can drive innovation, build trust, and create a more resilient future for their businesses.”
The research draws on surveys of global senior insurance executives and US customers, highlighting AI’s impact, challenges, and opportunities in the insurance sector.
Key findings
Wide adoption, limited impact on customers: While 69% of respondents report that their companies are using AI, only 36% of US consumers feel their digital experiences have improved in the last two years, revealing an opportunity to align internal effort with external outcomes. Trust in the accuracy of AI-driven insurance quotes remains low, with 59% of consumers preferring live agents over AI, especially during crises.
Most respondents have yet to see AI’s full potential: 62% of respondents believe competitive advantage will come from greater efficiency in high-volume tasks, while only 30% expect it from high-complexity tasks, and just 8% from using AI for growth or monetization. This suggests that AI capabilities are being underused.
Tech isn’t the biggest AI hurdle: Scaling AI faces challenges beyond technology. At 49%, and unlike past technology waves, governance and oversight are proving to be more significant challenges for insurers. Data privacy at 62% and regulatory differences across jurisdictions at 42% are concerns that exacerbate the problem, creating a landscape where a one-size-fits-all strategy simply doesn’t work. Proofs of concept may succeed in one area but fail elsewhere, requiring insurers to rethink their approaches.
AI fluency gap in the workforce Despite growing investment in training and partnerships, only 2% of insurance executives report that nearly all their team members are AI fluent. In fact, 69% say that either very few team members – or at best some – are AI fluent. This talent shortfall significantly limits the industry’s ability to scale AI effectively.
“The report highlights an industry poised for transformation, where scaling AI effectively can redefine customer experiences and build lasting trust,” said Yasir Andrabi, Agentic AI Leader, Insurance, Genpact. “With decades of experience designing and managing end-to-end processes and collaborating with insurers around the world, Genpact is uniquely positioned to help carriers navigate their AI journeys. We are driving transformative outcomes and positioning our clients for long-term success in a competitive industry.”
A strategic blueprint to scale AI
To support this transformation, the report proposes a six-point strategic blueprint for insurers to successfully scale AI: strengthening data foundations, building partnerships, empowering people, designing for scale, balancing governance and risk, and prioritizing business outcomes.
Leveraging its proven methodologies and commitment to advanced technology innovation, Genpact empowers insurers to implement these strategies effectively, enabling them to redefine customer experiences and build lasting trust in an evolving industry.
Discover more
Explore the state of AI adoption in insurance and practical guidance to overcome barriers, fuel innovation, and enhance customer value. Read the full report here.
For more information about Genpact’s work across the insurance industry, click here.
Methodology
The study surveyed 200 senior insurance executives worldwide and 1,000 US insurance customers, providing dual perspectives on AI’s impact. It also included in-depth interviews with 16 C-level executives, offering a deeper understanding of the challenges and opportunities shaping the industry.
Microbiome-focused company receives $6 million in funding to advance gut microbiome platform technologies
32 Biosciences, a leader in the field of gut microbiome medicine, today announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key regulatory milestones.
32 Biosciences’ diagnostic platform technology quantitatively evaluates the gut microbiome’s functional health, assessing its ability to support key bodily functions. Developed utilizing AI/machine learning and powered by mass spectrometry, this diagnostic management tool is intended to provide clinically actionable information and to support the development of microbiome-based interventions.
The company’s therapeutic innovation is a potential first-of-its-kind non-antibiotic antimicrobial designed to prevent gut-derived bacterial infections by inhibiting virulence gene expression, enhancing the gut mucosal barrier, and promoting beneficial bacteria growth. Proven effective in robust animal models, this potential therapy is expected to significantly reduce infection rates and infection-related mortality without contributing to antibiotic resistance, if approved by FDA, offering a transformative approach to infection prophylaxis.
“This is our second fundraise, and both times we exceeded our goals,” said Peter Farmakis, CEO of 32 Biosciences. “It’s a testament to our focused approach to restoring the functional health of the gut microbiome, our strong management team, and the groundbreaking science from the University of Chicago.” 32 Biosciences is progressing toward FDA clearance for its gut microbiome diagnostic management tool, which is targeted for late 2026. The funds will support key development milestones, including clinical validation, regulatory submissions, and commercial readiness.
The company is on track to submit its FDA Pre-Submission Meeting Package in late Q2, a pivotal step in securing regulatory clearance. Parallel progress continues in advancing 32 Biosciences’ lead therapeutic candidate, toward Phase I clinical trials.
Expanded Scientific & Business Advisory Boards
32 Biosciences has appointed five distinguished leaders to its Scientific & Business Advisory Boards to support its scientific and strategic growth:
Purna Kashyap, MD – Co-Director of the Microbiome Program at Mayo Clinic; expert in Functional Gastrointestinal Disorders and microbiome-host interactions.
David Rubin, MD – Professor and Section Chief at the University of Chicago; internationally recognized expert in inflammatory bowel disease (IBD) and precision medicine.
Jay Wohlgemuth, MD – Chief Medical Officer at Genesis BioCapital; former CMO, CSO, and SVP R&D at Quest Diagnostics with deep expertise in clinical diagnostics development and commercialization.
Jack Kalavritinos – CEO of JK Strategies; former Director at the U.S. Department of Health and Human Services (HHS), specializing in regulatory strategy and public affairs.
Don Potter – Former Executive at UnitedHealthcare Group; expert in payer strategy, reimbursement, and healthcare innovation.
“These appointments reinforce our commitment to scientific rigor and commercial readiness,” said Farmakis. “Their collective expertise will be instrumental as we advance our diagnostic and therapeutic platforms through development and into the market.”
Executive Team Expansion
32 Biosciences has also strengthened its leadership team with key promotions and strategic hires:
“Our expanded leadership team and advisory boards position us to scale operations and drive innovation across diagnostics and therapeutics,” Farmakis added. “We’re building the foundation for long-term impact in gut microbiome medicine.”
32 Biosciences is redefining the field of microbiome medicine through precision diagnostics and therapeutics. The company’s mission is to revolutionize healthcare by defining, diagnosing, and restoring the functional health of the gut microbiome to prevent and treat chronic diseases, thereby improving health span and longevity. For more information, visit www.32biosciences.com.
Legal Statements
Nothing in this press release constitutes an offer to buy, or a solicitation of an offer to sell, securities in the United States or any other jurisdiction in which such offer or solicitation would be unlawful.
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about 32 Biosciences’ beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement, and you should not place any undue reliance on these forward-looking statements. These factors include, but are not limited to, (i) capital market volatility, (ii) local and global economic conditions, (iii) our anticipated growth strategies, (iv) our ability to gain approval of our products with the U.S. Federal and Drug Administration, and (v) our future business development, results of operations and financial condition. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “prepare,” “on track” or other similar expressions. All information provided in this press release is as of the date of this press release, and 32 Biosciences undertakes no duty to update such information, except as required under applicable law.
New Workflow Streamlines Protein Structural Analysis and Supports the Growing Role of AI in Drug Discovery
GenNext® Technologies, Inc., a pioneer in protein footprinting, is collaborating with Thermo Fisher Scientific, the world leader in serving science, to provide a simplified structural biology workflow designed to improve biotherapeutic development. The organizations are combining GenNext’s AutoFox® Protein Footprinting System with Thermo Fisher’s industry-leading liquid chromatography-mass spectrometry (LC-MS) solutions, particularly Thermo Scientific™ Orbitrap™ instrumentation, sample preparation technology and other structural proteomics consumables, such as crosslinkers and fluorescence labels, to create a powerful, end-to-end workflow solution for researchers working on complex protein structure and drug interaction studies.
The integrated workflow delivers high-resolution insights into protein structure and dynamics—essential for optimizing drug safety, efficacy and delivery. It also offers researchers a valuable toolset to help validate structural models generated by artificial intelligence (AI), an emerging frontier in drug discovery.
“We’re thrilled to collaborate with Thermo Fisher Scientific in advancing the boundaries of structural biology,” said Scot Weinberger, CEO, GenNext Technologies. “By integrating our Fox® product line with Thermo Fisher’s MS instrumentation such as Thermo Scientific™ Orbitrap™ Tribrid™ MS or Thermo Scientific™ Orbitrap Exploris™ MS, advanced reagents and data processing software, researchers can rapidly gain unprecedented visibility into biomolecular structure and behavior with unprecedented speed and simplicity.”
High-Resolution Insights, Simplified Workflow
The workflow begins with GenNext’s AutoFox® system, which uses Radical Protein Footprinting to map protein shape, flexibility and binding interactions in near-native conditions. This structural information is then captured with high sensitivity and precision using Thermo Fisher’s Orbitrap mass spectrometers, supported by EasyPep™ Sample Prep Kits and Tandem Mass Tag reagents to enhance consistency, enable replicate pooling and maximize protein coverage. Leveraging the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer further uplifts the workflow by providing fast throughput, high sensitivity and deep proteome coverage to expedite protein discovery and characterization.
Data is processed using GenNext’s FoxWare® Software and Thermo Scientific’s Proteome Discoverer software, creating a seamless workflow from sample preparation to analysis and interpretation. The result is a simplified yet robust solution for structural biology research, especially important for the development of biologics and biosimilars.
“Structural biology is foundational to the understanding of the molecular basis of biological activity and for the development of new therapeutic strategies,” said Pushkin Pant, Vice President and General Manager of Life Sciences Mass Spectrometry at Thermo Fisher Scientific. “Our collaboration with GenNext, enables scientists to generate deeper, more actionable insights through a synergistic technology approach.”
Supporting the Next Generation of Drug Discovery
While AI tools are accelerating drug discovery by predicting protein structures and drug interactions, these predictions require experimental validation to become useful. The GenNext–Thermo Fisher workflow supports this effort by enabling researchers to efficiently test and refine AI-generated models—an approach already successfully demonstrated by GenNext’s researchers and clients.
This ability to combine speed, precision and real-world validation positions the workflow as a powerful asset in both traditional and AI-enhanced drug development.
About GenNext Technologies
GenNext Technologies, Inc., develops instrumentation, software, and services that help scientists understand and optimize the structure and behavior of therapeutic proteins. The company’s patented protein footprinting technology enables faster, safer, and more reproducible structural analysis—empowering researchers to accelerate drug development and improve therapeutic outcomes.
Nexus IT, a nationally recognized Managed Services and Cybersecurity provider, in partnership with Diatonic Healthcare, today announced a $60 million capital commitment from Metropolitan Partners Group. The investment will accelerate Nexus IT’s nationwide growth strategy, fueling its acquisition of culturally aligned managed service providers (MSPs) that share its vision of exceptional client service and operational excellence — specifically in highly regulated industries such as healthcare, finance, and legal.
This capital commitment marks a pivotal milestone in Nexus IT’s journey to build a next-generation M&A platform—one that stands apart from conventional investor rollups. Rather than pursuing scale at all costs, Nexus IT is expanding through a founder-led, mission-aligned approach focused on long-term value creation, cultural fit, and client-centric innovation.
“The capital from Metropolitan Partners Group enables us to grow with intention — not just faster, but better,” said Earl Foote, Founder and CEO of Nexus IT. “We’re not chasing volume. We’re building a platform rooted in shared values, leadership continuity, and a belief in our Mission that the IT experience should be as exceptional as the technology itself.”
Metropolitan Partners Group brings not only capital but deep operational expertise. The firm’s commitment to strategic alignment and values-based growth makes it a natural partner as Nexus IT scales its M&A efforts while preserving the leadership integrity and cultural DNA of the companies it acquires.
Richard Lin, Managing Director at Metropolitan Partners Group remarked: “We are excited to partner with Earl and his team at Nexus to grow a market leading MSP. Nexus has created a scalable platform for multiple acquisitions, and we are impressed with the company’s focus on purposeful growth and track record of success. It is exactly the type of founder owned and operated business that Metropolitan seeks to fund.”
“Together, we’re creating a new model for sustainable growth in the IT services industry—one where people, performance, and purpose drive every decision,” said Foote.
Nexus IT will use the investment to continue acquiring and integrating MSPs that exemplify strong client & employee relationships, industry expertise, and a commitment to service excellence. With several deals already in the pipeline, the company anticipates a significant expansion of its U.S. footprint over the next three years.
About Nexus IT Nexus IT is a national Managed Services and Cybersecurity provider delivering world-class IT support, strategy, and security solutions to clients in regulated and compliance-driven industries. Founded in 1998, Nexus IT is recognized for its exceptional service, people-first culture, and commitment to delivering secure and resilient technology environments for its clients.
About Metropolitan Partners Group Founded in 2008, Metropolitan Partners Group is a private investment firm that provides growth capital to non-sponsored businesses in the domestic lower middle market space, unconstrained by industry or asset class. The firm works directly with business owners and management teams to grow their balance sheets and build lasting value while aiming to provide downside protection to its investors. Metropolitan has deployed more than $3.1 billion and completed more than 160 transactions with companies across multiple business sectors. Visit www.metpg.com for more information.
About Diatonic Healthcare Diatonic Healthcare, LLC (“Diatonic”) is a Miami-based business builder focused on healthcare technology and tech-enabled services. Diatonic invests capital and time in a founder-friendly approach along with deeply thematic M&A and operational support. Since inception, Diatonic has carved out a niche in healthcare and regulated IT & Cyber. Visit www.diatonichealthcare.com.
